Protocol F1J-US-HMGO Neurobiology of Major Depressive Disorder

• Research type

  Research Study

• Full title

  Protocol F1J-US-HMGO - Neurobiological Correlates of Antidepressant Response After Duloxetine Hydrochloride Treatment in Subjects with Major Depressive Disorder

• IRAS ID

  27197

• Contact name

  Cynthia Fu

• Eudract number

  2009-013420-23

• ISRCTN Number

  n.a

• Clinicaltrials.gov Identifier

  n.a

• Research summary

  This is a phase 4 study being sponsored by Eli Lilly and Company. The aim of this study is to assess the neurobiology of Major Depressive Disorder (MDD) by comparing both medication-free patients with MDD with healthy volunteers and patients with MDD before and after treatment. MDD patients will be treated with duloxetine hydrochloride (60-120 mg QD) for a period of 12 weeks. A broad range of neurobiological measures will be assessed.

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  09/H0305/79

• Date of REC Opinion

  9 Nov 2009

• REC opinion

  Further Information Favourable Opinion